Agilent Technologies, Inc. - 10-Q Summary (Period Ended July 31, 2026)
Business Context and Reporting Period
This filing covers the quarterly period ended July 31, 2026 (Fiscal Q3 2026) and the nine-month period ended July 31, 2026. Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied markets, providing instruments, software, services, and consumables. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2026 | Nine Months Ended July 31, 2026 |
|---|---|---|
| Total Net Revenue | $1,878 million | $5,511 million |
| Net Income | $362 million | $1,006 million |
| Diluted EPS | $1.28 | $3.55 |
| Operating Margin | 23.6% | 21.7% |
| Gross Margin | 55.5% | 54.0% |
| Operating Cash Flow (9mo) | $1,064 million | |
| Cash and Equivalents (Balance Sheet) | $1,758 million | |
| Total Debt (Short + Long Term) | $3,949 million |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 8% year-over-year (YoY) for both the quarter and the nine-month period. Growth was driven by all segments and geographic regions.
- Profitability: Operating income increased 23% YoY for the quarter ($444 million vs. $360 million) and 15% for the nine months ($1,196 million vs. $1,036 million). Operating margin expanded 3 percentage points for the quarter and 1 percentage point for the nine months.
- Acquisition Impact: On June 24, 2026, Agilent acquired Biocare for a net consideration of $950 million. This acquisition added $549 million to goodwill and $520 million to intangible assets, primarily within the Life Sciences and Diagnostics Markets segment.
- Debt Issuance: On June 25, 2026, the company issued $600 million in 2032 Senior Notes at a 4.90% fixed interest rate.
- Share Repurchases: Under the 2024 repurchase program, the company repurchased 2.212 million shares for $295 million during the nine months ended July 31, 2026.
Guidance, Outlook, and Risks
- Outlook: Management remains optimistic about long-term growth, citing normalized customer capital budgets. The company expects to continue investing in R&D and expanding in emerging markets.
- Tariffs and Geopolitics: The company has mitigated adverse impacts from tariffs and Middle East conflicts through supply chain optimization and pricing actions. A net benefit from tariff refunds contributed approximately 1 percentage point to operating margin improvement in the quarter.
- Restructuring: Two restructuring plans (FY25 and FY26) are ongoing. The FY26 plan, initiated in Q3 2026, is expected to result in $30-$35 million in annual cost savings. Total restructuring expense for the nine months was $43 million.
- Risks: Key risks include global economic conditions, foreign currency fluctuations, supply chain disruptions, and the integration of acquired businesses. The company notes that tax audits may be completed in the next 12 months, though no material impact is currently estimated.
Investor Verification Checklist
- Biocare Integration: Verify the timeline for realizing revenue synergies and cost savings from the $950 million Biocare acquisition.
- Tariff Refund Realization: Monitor the status of IEEPA tariff refund claims and the timing of cash recoveries, as these are contingent on legal and administrative developments.
- Debt Servicing: Review the impact of the new $600 million 2032 Senior Notes on future interest expense and cash flow.
- Inventory Levels: Inventory days on hand increased to 120 days (from 107 days last year) due to strategic purchases to mitigate tariff risks; monitor for potential obsolescence if demand softens.
- Restructuring Execution: Track the progress of the FY26 restructuring plan to ensure the targeted $30-$35 million in annual savings is achieved by Q1 FY2027.